Eli Lilly and Company (LLY)
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
📈 **POSITIVE** • Low confidence analysis (38%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (75%) **Content type:** General